ABSTRACT
INTRODUCTION

38
Inadequate treatment of infections among patients requiring intensive care unit 39 (ICU) admission is an important determinant of hospital mortality(1). Drug dosing 40
should be considered an essential part of optimizing antibiotic use. However, 41 critically ill patients have been shown to have significant pharmacokinetic variability 42 for some antibiotics due to the physiological changes associated with this 43 pathology(2). This variability has been shown to impact on the achievement of 44 therapeutic exposures of antibiotics(3-7). If not considered in dosing regimens this 45 pharmacokinetic variability can lead to clinical failure or toxicity (8) . 46
47
Fosfomycin is a broad-spectrum antibiotic with bactericidal activity against various 48
Gram-negative and Gram-positive bacteria, and has been gaining considerable 49 attention recently due to its effectiveness as a treatment for multi-drug resistant 50 pathogens(9), including extended spectrum beta-lactamase and carbapenemase -51 producing bacteria. Fosfomycin exhibits extensive penetration into many tissue 52 types (10-13) and is well tolerated, with only minor adverse events 53
reported (14) , (15) . However, there is little data on the pharmacokinetics of this 54 potentially valuable antibiotic in critically ill patients and as such, significant 55 uncertainty relating to appropriate dosing exists. were collected as a routine procedure in all patients, with creatinine clearance (CL CR ) 83 calculated daily using the Cockcroft-Gault equation (19) . A measured urinary CL CR 84 over a 24 h time period was collected on the first day of sampling. Serum 85 biochemistry, including albumin concentrations, white cell count, and bilirubin 86 concentrations, were recorded. Concomitant antibiotic treatment was also recorded, 87 as was length of stay in the ICU and hospital, overall mortality and outcome of 88 treatment. 89
90
FOSFOMYCIN TREATMENT
91
In accordance with the study protocol treatment with fosfomycin was added to 92 therapy only after the culture results became available. The fosfomycin MIC was 93 determined by Etest (Biomerieux, Marcy-I' Etoile, France). Results were interpreted 94 according to EUCAST 2014 criteria (20) . Administration of fosfomycin was by IV 95 infusion over 30 to 60 minutes in accordance with local guidelines. The choice of 96 antibiotic dose was at the discretion of the treating physician; with doses of 4 or 6 g 97 of fosfomycin used at a frequency of three or four times daily, common in both ICUs. 98 6 administration of fosfomycin. Where possible sampling occurred during the first 104 dosing interval and/or on days 2, 4, 5, 6 and 7. 105
106
DRUG ASSAY
107
Plasma fosfomycin concentrations were determined using a high performance liquid 108 chromatography tandem mass spectrometry method previously described (21) at 109 the Burns Trauma and Critical Care Research Centre, The University of Queensland, 110
Australia. The assay inter-day coefficients of variation for fosfomycin in plasma were 111 ≤9.1 %, with an accuracy range of -7.2 to 3.3 %. The assay limit for plasma was 1 112 mg/L, with precision at 3.6 %, and accuracy of 1.1 %. The linearity of the assay (r 
PHARMACOKINETIC AND STATISTICAL ANALYSIS
116
The concentration-time data was analysed using non-linear mixed-effects modeling 117 (NONMEM version 7.3, Globomax LLC, Hanover, MD, USA). A digital Fortran compiler 118 was used and the runs were executed using Wings for NONMEM 119 (http://wfn.sourceforge.net). First-order conditional estimation method with 120 interaction was used throughout the model building. 121
122
Model Development 123
For the population pharmacokinetic analysis, the one-and two-compartment linear 124 models were fitted into plasma fosfomycin concentration data, using subroutines 125 from the NONMEM library. Between-subject variability (BSV) was best described 126 using an exponential variability model. Residual unexplained variability was tested 127 using various model iterations. 128
Model Diagnostics 129
The goodness of fit of the model was evaluated using visual inspection of diagnostic 130 scatter plots and the NONMEM objective function (OFV A NONMEM non-parametric bootstrap method (n=1000) was used to describe the 143 uncertainty of the pharmacokinetic parameter estimates in the final model. Using 144 the bootstrap empirical posterior distribution we obtained the 95% confidence 145 interval (CI, 2.5 to 97.5 percentiles) for the model parameters, using methods 146 previously described (22) . 147
RESULTS
149
Patient Characteristics 150
A total of 515 plasma samples were collected over one to six dosing intervals from 151 12 enrolled patients. The demographic and clinical characteristics of the patients are 152
shown in Table 1 . All patients received a dose of 6 g of fosfomycin every 6 hours, 153 except for patients 7 and 9. Patient 7 received a dose of 4 g of fosfomycin every 6 154 hours and patient 9 received a dose of 6 g of fosfomycin every 8 hours. The 155 microbiology for these infections, concomitant antibiotics and patient outcomes are 156 described in Table 2 . All patients were diagnosed as having septic shock and 157 respiratory failure and all patients were intubated. Where TVCL is the typical value of CL and θ 1-6 is the typical value of fosfomycin CL in 183 the population, with each sampling day defined as an individual θ, from Day 1 (θ 1 ), 2 184 (θ 2 ), 4 (θ 3 ), 5 (θ 4 ), 6 (θ 5 ), and 7 (θ 6 ). CL CR was normalized to the mean value for the 185 patients and WT is patient weight. TVVc is the typical value of Vc. The mean apparent volume of distribution in this study was 48.8 L, which is higher 216 than that observed by Kirby (22 L) (23) in healthy volunteers, and is likely to due to 217 presence of greater sickness severity. A larger than normal volume of distribution is 218 one of the typical pathophysiological changes observed in critically ill patients and 219 has been reported in multiple pharmacokinetic studies for different antibiotics (7, 220
24). 221 222
In this study of twelve patients, two patients consistently had CL CR >200 mL/min. 223
Augmented renal clearance -defined as a sustained elevation of CL CR (>130 224 mL/min/1.73m 2 ) -manifests in over 65% of critically ill patients in the first week of 225 admission into an ICU (25) and, as seen in this study, is likely to impact on the 226 probability of attainment of therapeutic exposures of renally cleared antibiotics. 227
Renal insufficiency is associated with dramatically higher fosfomycin concentrations, 228 and two patients consistently had CL CR <50mL/min/1.73m 2 . The pharmacokinetic 229 variability observed in this study is explained somewhat by the wide ranges of renal 230
function. 231 232
This study has some limitations we would like to declare. We have not measured 233 free concentrations of fosfomycin in plasma, or the concentrations at the site of 234 infection. Instead we have measured the total drug concentration. However, the 235 antimicrobial activity of fosfomycin has been shown to not be affected by the 236 presence of albumin (26) and is considered to have negligible protein binding. Also, 237
given this study is of a relatively small cohort of twelve patients, and given the high 238 extremes of renal function in patients and sample collection over up to 6 dosing 239 on August 27, 2017 by guest http://aac.asm.org/ Downloaded from intervals, this could also be considered a limitation. Indeed the small heterogeneous 240 sample may also impact on the model being able to identify other relevant 241 covariates, although this number of patients provides useful data from which 242 clinicians can use to procure more relevant doses (27). The visual predictive check 243 (Fig 1b) suggests there is a small overestimation of higher concentrations from the 244 model, compared to the individual data points in the later days of sampling. Legend: BSV -between subject variability; CV -coefficient of variation
